<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="research-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">WASJ</journal-id>
<journal-title-group>
<journal-title>World Academy of Sciences Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">2632-2900</issn>
<issn pub-type="epub">2632-2919</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">WASJ-6-1-00221</article-id>
<article-id pub-id-type="doi">10.3892/wasj.2024.221</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Assessment of gankyrin mRNA expression in tissue and liquid biopsy as a sensitive biomarker for hepatocellular carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gogichaishvili</surname><given-names>Levan</given-names></name>
<xref rid="af1-WASJ-6-1-00221" ref-type="aff">1</xref>
<xref rid="af2-WASJ-6-1-00221" ref-type="aff">2</xref>
<xref rid="c1-WASJ-6-1-00221" ref-type="corresp"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Lobzhanidze</surname><given-names>Gia</given-names></name>
<xref rid="af1-WASJ-6-1-00221" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schlit</surname><given-names>Hans J.</given-names></name>
<xref rid="af3-WASJ-6-1-00221" ref-type="aff">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bedinashvili</surname><given-names>Zanda</given-names></name>
<xref rid="af4-WASJ-6-1-00221" ref-type="aff">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sharvadze</surname><given-names>Lali</given-names></name>
<xref rid="af5-WASJ-6-1-00221" ref-type="aff">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Goishvili</surname><given-names>Nana</given-names></name>
<xref rid="af4-WASJ-6-1-00221" ref-type="aff">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jangavadze</surname><given-names>Mikheil</given-names></name>
<xref rid="af4-WASJ-6-1-00221" ref-type="aff">4</xref>
</contrib>
</contrib-group>
<aff id="af1-WASJ-6-1-00221"><label>1</label>Department of Surgery, Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, 0179 Tbilisi, Georgia</aff>
<aff id="af2-WASJ-6-1-00221"><label>2</label>Israeli-Georgian Medical Research Clinic ‘Healthycore’, 0154 Tbilisi, Georgia</aff>
<aff id="af3-WASJ-6-1-00221"><label>3</label>Department of Surgery, University Clinic of Regensburg, D-93053 Regensburg, Germany</aff>
<aff id="af4-WASJ-6-1-00221"><label>4</label>Aleqsandre Natishvili Institute of Morphology, Ivane Javakhishvili Tbilisi State University, 0159 Tbilisi, Georgia</aff>
<aff id="af5-WASJ-6-1-00221"><label>5</label>Infectious Diseases, AIDS and Clinical Immunology Research Center, 0160 Tbilisi, Georgia</aff>
<author-notes>
<corresp id="c1-WASJ-6-1-00221"><italic>Correspondence to:</italic> Dr Levan Gogichaishvili, Department of Surgery, Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, 1 Chavchavadze Avenue, 0179 Tbilisi, Georgia <email>levangogich@gmail.com tsatsaka@uoc.gr </email></corresp>
</author-notes>
<pub-date pub-type="collection">
<season>Jan-Feb</season>
<year>2024</year></pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>01</month>
<year>2024</year></pub-date>
<volume>6</volume>
<issue>1</issue>
<elocation-id>6</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>12</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © Gogichaishvili et al.</copyright-statement>
<copyright-year>2023</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license>
</permissions>
<abstract>
<p>The early diagnosis of hepatocellular carcinoma (HCC) and the detection of disease recurrence are vital for the improvement of patient survival. The aim of the present study was to investigate the use of circulating plasma gankyrin mRNA expression as a potential biomarker for patient management. A total of 64 patients and healthy volunteers were recruited in the present study [54 individuals and 10 archived material of formalin-fixed paraffin-embedded samples (5 normal liver samples were obtained from transplant donors and 5 from patients undergoing cirrhotic liver biopsy)]. The blood plasma of patients with HCC (n=32), metastatic HCC (n=5), cirrhosis (n=7), hepatitis C virus<sup>+</sup> (HCV<sup>+</sup>; n=5) and healthy individuals (n=5) was evaluated. The expression levels of gankyrin/PSMD10 mRNA in tissue samples from patients with HCC (tumor and adjacent; n=32), cirrhosis (n=5) and normal liver (n=5) were evaluated. RNA extraction from peripheral blood and formalin-fixed paraffin-embedded tissue samples and reverse-transcription-quantitative polymerase chain reaction were performed using commercially available kits according to standard procedures. The relative expression levels were calculated using the 2<sup>-ΔΔCq</sup> method. In patients with cirrhosis, HCV<sup>+</sup> and healthy individuals, gankyrin/PSMD10 RNA was not determined. In all patients with either HCC or metastatic HCC, target RNA was detected. The mean gankyrin/PSMD10 expression in tissues exhibited significant differences between groups. Evidence was provided that gankyrin RNA expression was significantly increased in HCC compared with that in normal and cirrhotic tissues. Gankyrin RNA was not detectable in the blood plasma of healthy individuals and individuals without cancer, while its expression was significantly increased in the plasma of patients with HCC. Gankyrin RNA in liquid biopsy can thus be used for screening patients who belong to the risk groups for the development of HCC. Since gankyrin is not specific for HCC, it needs to be used with other markers for the diagnosis of HCC, although it can be used alone for the early detection of tumor recurrence.</p>
</abstract>
<kwd-group>
<kwd>hepatocellular carcinoma</kwd>
<kwd>tumor marker</kwd>
<kwd>liquid biopsy</kwd>
<kwd>gankyrin</kwd>
<kwd>liver</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> The present study was supported by the Shota Rustaveli National Science Foundation of Georgia SRNSFG (#PhD_F_17_33).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies. It is the third leading cause of malignant tumor-related mortality; the fifth most common among males and the seventh most common among females (<xref rid="b1-WASJ-6-1-00221" ref-type="bibr">1</xref>). At the early stages of the disease (stages 0-A), the tumor is considered curable; however, in 60% of HCC cases, the disease is diagnosed at advanced stages when the average life expectancy, despite treatment, is only 8 months, while the relevant life expectancy at the middle stages of the disease is 26 months (<xref rid="b2-WASJ-6-1-00221" ref-type="bibr">2</xref>,<xref rid="b3-WASJ-6-1-00221" ref-type="bibr">3</xref>). Furthermore, surgical treatment as an ideal, curative treatment option is available only at the early stages of cancer. Therefore, the early diagnosis of HCC and the monitoring of disease recurrence are vital for the improvement of patient survival.</p>
<p>Over the past decade, a number of molecular techniques were introduced in basic and clinical oncology. Liquid biopsy (LB) is one such diagnostic modality (<xref rid="b4-WASJ-6-1-00221" ref-type="bibr">4</xref>). Initially, it was used for the detection of circulating tumor cells in blood; however, it now includes other tumor-related components, such as DNA, RNA, microRNA (miRNA/miR) and proteins (<xref rid="b5-WASJ-6-1-00221" ref-type="bibr">5</xref>,<xref rid="b6-WASJ-6-1-00221" ref-type="bibr">6</xref>). LB has not yet become a routine clinical test, although its high potential for tumor detection, molecular profiling, surgical radicality monitoring and treatment outcome prediction is evident (<xref rid="b7-WASJ-6-1-00221" ref-type="bibr">7</xref>). Compared with the tumor core biopsy technique, LB is a less invasive procedure using body fluids, including blood, for analyses (<xref rid="b8-WASJ-6-1-00221" ref-type="bibr">8</xref>). The development of the LB technique led to the use of tumor-related nucleic acids as biomarkers for cancer. Plasma-derived tumor-related RNA was of particular interest.</p>
<p>Gankyrin, also known as PSMD10 or p28GANK, is a small molecular protein composed of seven ankyrin domains and is a component of the 26S proteasome (<xref rid="b9-WASJ-6-1-00221 b10-WASJ-6-1-00221 b11-WASJ-6-1-00221" ref-type="bibr">9-11</xref>). It is encoded by the PSMD10 gene and plays a crucial role in cell cycle progression, apoptosis and tumorigenesis. Initially, gankyrin was identified in human HCC (<xref rid="b12-WASJ-6-1-00221" ref-type="bibr">12</xref>); however, several studies have demonstrated that gankyrin expression is upregulated in other types of cancer (for example kidney, breast, testicular cancer and squamous cell carcinoma) as well (<xref rid="b13-WASJ-6-1-00221 b14-WASJ-6-1-00221 b15-WASJ-6-1-00221" ref-type="bibr">13-15</xref>).</p>
<p>Numerous studies have demonstrated that p28GANK is one of the main factors involved in hepatocellular carcinogenesis. Gankyrin protein expression is increased not only in HCC tissues, but also in cirrhotic liver, while it is absent in normal liver samples (<xref rid="b16-WASJ-6-1-00221 b17-WASJ-6-1-00221 b18-WASJ-6-1-00221 b19-WASJ-6-1-00221 b20-WASJ-6-1-00221" ref-type="bibr">16-20</xref>). In another study, the lowest level of gankyrin protein was found in the normal liver, while its expression was notably increased in HCC, and the level was highest in metastatic HCC (<xref rid="b21-WASJ-6-1-00221" ref-type="bibr">21</xref>). A previous study demonstrated that gankyrin was associated with cell cycle and tumor progression (<xref rid="b22-WASJ-6-1-00221" ref-type="bibr">22</xref>). As shown by several studies, gankyrin can promote HCC metastasis by enhancing epithelial-mesenchymal transition via the PI3K/Akt/HIF-1α signaling pathway (<xref rid="b21-WASJ-6-1-00221" ref-type="bibr">21</xref>,<xref rid="b23-WASJ-6-1-00221 b24-WASJ-6-1-00221 b25-WASJ-6-1-00221" ref-type="bibr">23-25</xref>). These findings indicate that gankyrin may be used as a diagnostic and prognostic marker for HCC and for monitoring tumor recurrence.</p>
<p>Despite increased evidence of the role of gankyrin in HCC and other tumors, to the best of our knowledge, there are currently no studies available on circulating cell-free RNA for gankyrin in the blood plasma of patients with cancer. As a biomarker, circulating cell-free RNA has some advantages due to its stability, the non-invasive method used for its collection and the accuracy of the obtained quantitative data.</p>
<p>The aim of the present study was to investigate the feasibility of plasma circulating gankyrin mRNA expression as a potential biomarker for HCC. The expression p28GANK RNA was analyzed in the blood plasma, as well as in the tumor and non-tumor liver tissue of patients with HCC and cirrhosis, and in healthy individuals.</p>
</sec>
<sec sec-type="Materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Blood and formalin-fixed paraffin-embedded (FFPE) tissue samples-study design</title>
<p>A total of 64 patients and healthy volunteers were recruited in the present study, 54 individuals from whom blood was collected and 10 archived material of FFPE (5 normal liver samples were obtained from transplant donors and 5 from patients undergoing cirrhotic liver biopsy) (<xref rid="tI-WASJ-6-1-00221" ref-type="table">Tables I</xref> and <xref rid="tII-WASJ-6-1-00221" ref-type="table">II</xref>). All participants provided written informed consent prior to enrolment. The present study was approved by the Institutional Ethics Committee of the Alexandre Natishvili Institute of Morphology (Ivane Javakhishvili Tbilisi State University). All patients were admitted to the ‘Israeli-Georgian Medical Research Clinic Healthycore’.</p>
<p>To investigate the expression of the gankyrin/PSMD10 gene in the plasma of patients with HCC, blood samples from patients with HCC (n=32), metastatic HCC (n=5), cirrhosis (n=7), hepatitis C virus<sup>+</sup> (HCV<sup>+</sup>; n=5) and healthy individuals (n=5) were evaluated. All patients with HCC had cirrhosis and sustained virologic response (SVR) following previous direct-acting antiviral treatment. In the group ‘HCV<sup>+</sup> individuals’, patients with newly-diagnosed active HCV hepatitis without cirrhosis and HCC were included. In the group ‘patients with cirrhosis’, patients without HCC and with SVR were included. The ‘HCC group’ consisted of 32 patients, 5 females (15.6%) and 27 males (84.4%). The mean age of the patients was 55.7 years (±5.7; range, 46-66 years). The group of patients with metastatic HCC consisted of 5 male individuals with mean age 57.4 years (±3.6; range, 52-62 years). The mean age of the 7 patients with cirrhosis was 57.1 years (±2.9; range, 53-61 years), and among these, there was 1 female patient (14.3%) and 6 male patients (85.7%). The group of patients with HCV infection consisted of 5 individuals, including 1 female (20%) and 4 males (80%) with a mean age of 49.4 years (±1.7; range 48-52 years). Among the 5 healthy volunteers, there was 1 female (20%) and 4 males (80%) without a history of neoplasm, liver and other organ chronic disease. The mean age of the healthy volunteers was 50.0 years (±4.1; range, 45-55 years). The clinical characteristics of the patients in all the study groups are presented in <xref rid="tI-WASJ-6-1-00221" ref-type="table">Table I</xref>.</p>
<p>The expression of gankyrin/PSMD10 RNA was analyzed in tumor tissue samples from patients with HCC (tumor and adjacent; n=32), cirrhosis (n=5) and normal tissues obtained from living donors prior to transplantation for liver graft quality assessment (n=5). The HCC group consisted of the same patients as in the case of blood plasma. Tumor adjacent tissue (ADJ T) was collected from only 27 cases, as 5 patients only had biopsy samples, as surgery was not indicated. The group of patients with cirrhosis consisted of 5 male individuals (100%). The mean age was 50.4 years (±2.1; range, 48-53 years). The mean age of the healthy liver donors was 35.6 years (±3.04; range, 32-40 years), including 1 female (20%) and 4 males (80%). The clinical characteristics of all the involved individuals are presented in <xref rid="tII-WASJ-6-1-00221" ref-type="table">Table II</xref>.</p>
</sec>
<sec>
<title>RNA extraction from peripheral blood samples</title>
<p>Plasma samples were isolated from 4 ml peripheral blood using BD Vacutainer<sup>®</sup> Blood Collection Tubes (EDTA-K2 was used as an anticoagulant; BD Biosciences). The tubes were centrifuged at 1,610 x g for 15 min, and 1 ml supernatant plasma was transferred to 1.5 ml tubes and stored at -80˚C until use. Fresh total DNA/RNA/miRNA was extracted from blood plasma using the RecoverAll™ Total Nucleic Acid Isolation kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's recommendations. Total nucleic acid concentration was measured using a NanoDrop™ ND-1000 Spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.).</p>
</sec>
<sec>
<title>Tumor RNA extraction from FFPE tissue samples</title>
<p>The starting material for RNA purification was freshly cut sections of FFPE tissue, each with a thickness of up to 20 µm. Up to 4-20 µm sections from each FFPE tissue block were combined and placed in a 1.5-ml microcentrifuge tube. Total DNA/RNA was extracted from the FFPE tissues of tumor, adjacent liver and control samples using the RecoverAll™ Total Nucleic Acid Isolation kit for FFPE (Thermo Fisher Scientific, Inc.) according to the manufacturer's recommendations. The RNA concentrations and purity were determined using a Nanodrop1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). The A260/280 and A260/A230 ratios were recorded along with the RNA concentration (ng/ml). The RNA samples with a A260/A280 ratio ranging from 1.8 to 2.1 were considered of good purity.</p>
</sec>
<sec>
<title>Reverse-transcription-quantitative polymerase chain reaction (RT-qPCR)-p28/gankyrin</title>
<p>RT-qPCR was performed using TaqPath™ 1-Step Multiplex Master Mix (No ROX; cat. no. A28522; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Human 18S ribosomal RNA was used as an internal reference gene. Each sample was run in duplicate. The RT-qPCR protocol included an initial denaturation step at 95˚C for 20 sec and 40 cycles of denaturation at 95˚C for 3 sec and annealing at 60˚C for 30 sec. The relative expression levels were calculated using 2<sup>-ΔΔCq</sup> method as previously described (<xref rid="b26-WASJ-6-1-00221" ref-type="bibr">26</xref>). cDNA was amplified using the following Taqman<sup>®</sup> assays: p28/Gankyrin-(Assay ID Hs01100439_g1) and human 18S ribosomal RNA-(Assay ID Hs99999901_s1; Thermo Fisher Scientific, Inc.).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The Mann-Whitney U test was used to determine the statistical significance for comparisons data of 2<sup>-ΔΔCq</sup> and fold change. For multiple comparisons, the non-parametric Kruskal-Wallis test followed by the Dunn's post hoc test was. Statistical analyses were carried out using SPSS (version 23.0; IBM Corp.) and GraphPad Prism (version 8.0; Dotmatics).</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<p>The plasma gankyrin/PSMD10 RNA level was examined using RT-qPCR in the patients with HCC (n=32), metastatic HCC (n=5), cirrhosis (n=7), HCV<sup>+</sup> (n=5) and healthy individuals (n=5). In patients with cirrhosis, HCV<sup>+</sup> and healthy individuals, gankyrin/PSMD10 RNA was not detected by the method described in the present study. ∆Cq (target gene Cq - housekeeping gene Cq) was calculated for every sample. The mean ∆Cq in HCC group was 11.69±1.6, and in patients with metastatic HCC it was 10.16±0.4. A statistically significant difference in the ∆Cq was found between the groups (mean difference, 1.532; 95% CI of difference, 0.7444-2.3200; P&lt;0.0002; <xref rid="f1-WASJ-6-1-00221" ref-type="fig">Fig. 1</xref>).</p>
<p>A significant difference in the gankyrin expression level was found in the tissue samples. The 2<sup>-ΔΔCq</sup> mean for gankyrin/PSMD10 in HCC, HCC ADJ T, cirrhosis and control group was 418.5±220.6, 78.68±49.40, 20.62±11.32 and 1.02±0.23, respectively. The differences between groups were statistically significant (P&lt;0.001; <xref rid="f2-WASJ-6-1-00221" ref-type="fig">Fig. 2</xref>).</p>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>Several studies have used LB in the clinical management of HCC, including the research for early detection, monitoring of disease and prediction of response (<xref rid="b27-WASJ-6-1-00221 b28-WASJ-6-1-00221 b29-WASJ-6-1-00221 b30-WASJ-6-1-00221 b31-WASJ-6-1-00221 b32-WASJ-6-1-00221 b33-WASJ-6-1-00221 b34-WASJ-6-1-00221" ref-type="bibr">27-34</xref>). In these studies, different molecular panels were used; however, satisfactory levels of specificity and sensitivity were not achieved. Thus, the identification of novel potential targets is critical in order to obtain desirable results for clinical implementation.</p>
<p>In the present study, to the best of our knowledge, the differential expression of gankyrin RNA in the serum and liver tissues samples from patients with HCC and from healthy individuals was reported for the first time, identifying novel potential biomarkers with a high diagnostic capacity.</p>
<p>Several findings can be highlighted in the results of the present study. First, the gankyrin RNA level in HCC tumor tissue was significantly higher, not only compared with that in healthy liver tissue, but also compared with that in adjacent and cirrhotic livers. Thus, it can be added as an ancillary study for the differential diagnosis of liver malignant and benign or reactive nodules on biopsy. Furthermore, in the liver tissue adjacent to the tumor, which is naturally cirrhotic liver, the gankyrin RNA level was also higher than that in the cirrhotic liver tissues of patients without HCC. It is not clear if this is a consequence of adjacent ‘malignant’ process, or whether the upregulation is a first step of ‘malignant’ transformation of hepatocytes. If the latter was confirmed, a good prediction marker for patients with cirrhosis would have been identified to determine the risk of HCC development.</p>
<p>Secondly, the data from the expression of gankyrin RNA in blood plasma revealed promising results. In healthy individuals, individuals with an HCV infection and in patients with cirrhosis, gankyrin RNA was not detectable at all in blood plasma, while it was detectable in all patients with either local HCC or metastatic disease. These findings indicate the potential of gankyrin RNA alone or in combination with other genetic markers to be used as a clinical biomarker for early detection, the monitoring of disease and the prediction of the response in patients with HCC.</p>
<p>Although additional research on gankyrin RNA is required, the findings of the present study, together with other clinical and instrumental data, may be informative for the management of HCC, particularly in cases where other studies did not provide a clear result. In addition, this marker would enable the detection of HCC at a stage when it is impossible to make a full diagnosis with computed tomography, ultrasound and MRT data.</p>
<p>For example, in the case of the Liver Imaging Reporting and Data System-3 (LiRads-3) lesion during cirrhosis, the patient is monitored for a long period of time, since the aforementioned type of lesion does not indicate a malignant tumor, but due to the presence of pathogenic risks, it is considered a potential danger. With the result of the LB, it may be possible to differentiate a malignant tumor in LiRads-3 lesions from a hyperplastic nodule, which occurs as an ordinary case in liver cirrhosis.</p>
<p>Although the present study included a relatively small number of patients, it provided promising and solid results, and could lay the foundation for further research conducted towards this direction, as well as for the detection of an improved molecular panel together with gankyrin to diagnose early-stage HCC.</p>
<p>The method described in the present study is less invasive and enables the determination of the molecular profile using blood plasma. LB is a simple diagnostic tool for early detection of malignancy in risk groups, such as those infected with HCV and hepatitis B virus for a long time, cirrhosis of the liver and non-alcoholic fatty liver disease. In addition, gankyrin RNA as a biomarker may be suitable for monitoring HCC recurrence.</p>
<p>The present study has certain limitations, which should be mentioned. First, the present study was conducted on a relatively small group of patients and needs to be confirmed in a larger case series involving different centers. Second, the present study did not include follow-up data of patients, which would be proof of the ability of gankyrin RNA in LB to be used for the early detection of HCC recurrence. As an LB marker, gankyrin RNA must be validated in patients with different liver tumors and also secondary ones.</p>
<p>In conclusion, the data of the present study provide strong evidence that the expression of gankyrin RNA is significantly increased in HCC compared with that in normal and cirrhotic tissues. In the tumor adjacent liver tissue, the gankyrin RNA level was higher than that in the cirrhotic liver tissues of patients without HCC. Gankyrin RNA was not detectable in the blood plasma of healthy individuals and in that of patients without cancer; however, its expression was significantly increased in the plasma of patients with HCC. The detection of gankyrin RNA in LB can be practically used for screening patients who belong to the risk groups for the development of HCC.</p>
<p>Since gankyrin is not specific for HCC, it must be used with other molecular markers for the diagnosis of HCC, but it can be used alone for the monitoring and early detection of tumor recurrence. To prove this hypothesis, future studies are warranted, which must include data regarding gankyrin RNA expression levels in the blood samples before and after the resection of HCC and validation at the protein level.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Professor Dimitri Kordzaia (Director of the Aleqsandre Natishvili Institute of Morphology) for providing the necessary research facilities.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors' contributions</title>
<p>All authors (LG, GL, HJS, ZB, LS, NG and MJ) contributed to the conception and design of the study. Material preparation was performed by LG, LS, NG and MJ. Data collection and analysis were performed by MJ, ZB and LG. Analysis was performed by ZB, HJS and GL. ZB and NG confirm the authenticity of all the raw data. The first draft of the manuscript was written by LG and all authors commented on previous versions of the manuscript. All authors have read and approved the final version of the manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The present study was approved by the Institutional Ethics Committee of the Alexandre Natishvili Institute of Morphology (Ivane Javakhishvili Tbilisi State University; approval no. N06/18) and written informed consent was provided by the patients. The present study was conducted in accordance with the Declaration of Helsinki.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-WASJ-6-1-00221"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goossens</surname><given-names>N</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name></person-group><article-title>Hepatitis C virus-induced hepatocellular carcinoma</article-title><source>Clin Mol Hepatol</source><volume>21</volume><fpage>105</fpage><lpage>114</lpage><year>2015</year><pub-id pub-id-type="pmid">26157746</pub-id><pub-id pub-id-type="doi">10.3350/cmh.2015.21.2.105</pub-id></element-citation></ref>
<ref id="b2-WASJ-6-1-00221"><label>2</label><element-citation publication-type="journal"><comment>European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer</comment><article-title>EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma</article-title><source>J Hepatol</source><volume>56</volume><fpage>908</fpage><lpage>943</lpage><year>2012</year><pub-id pub-id-type="pmid">22424438</pub-id><pub-id pub-id-type="doi">10.1016/j.jhep.2011.12.001</pub-id></element-citation></ref>
<ref id="b3-WASJ-6-1-00221"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Decaens</surname><given-names>T</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Boucher</surname><given-names>E</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Assenat</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><etal/></person-group><article-title>Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study</article-title><source>J Clin Oncol</source><volume>31</volume><fpage>3509</fpage><lpage>3516</lpage><year>2013</year><pub-id pub-id-type="pmid">23980090</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2012.47.3009</pub-id></element-citation></ref>
<ref id="b4-WASJ-6-1-00221"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Alix-Panabieres</surname><given-names>C</given-names></name></person-group><article-title>Circulating tumour cells in cancer patients: Challenges and perspectives</article-title><source>Trends Mol Med</source><volume>16</volume><fpage>398</fpage><lpage>406</lpage><year>2010</year><pub-id pub-id-type="pmid">20667783</pub-id><pub-id pub-id-type="doi">10.1016/j.molmed.2010.07.001</pub-id></element-citation></ref>
<ref id="b5-WASJ-6-1-00221"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>E</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name></person-group><article-title>Liquid biopsy: Monitoring cancer-genetics in the blood</article-title><source>Nat Rev Clin Oncol</source><volume>10</volume><fpage>472</fpage><lpage>484</lpage><year>2013</year><pub-id pub-id-type="pmid">23836314</pub-id><pub-id pub-id-type="doi">10.1038/nrclinonc.2013.110</pub-id></element-citation></ref>
<ref id="b6-WASJ-6-1-00221"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Ni</surname><given-names>C</given-names></name><name><surname>Xin</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Liquid biopsy for cancer: Circulating tumor cells, circulating free DNA or exosomes?</article-title><source>Cell Physiol Biochem</source><volume>41</volume><fpage>755</fpage><lpage>768</lpage><year>2017</year><pub-id pub-id-type="pmid">28214887</pub-id><pub-id pub-id-type="doi">10.1159/000458736</pub-id></element-citation></ref>
<ref id="b7-WASJ-6-1-00221"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Application of liquid biopsy in precision medicine: Opportunities and challenges</article-title><source>Front Med</source><volume>11</volume><fpage>522</fpage><lpage>527</lpage><year>2017</year><pub-id pub-id-type="pmid">28744793</pub-id><pub-id pub-id-type="doi">10.1007/s11684-017-0526-7</pub-id></element-citation></ref>
<ref id="b8-WASJ-6-1-00221"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinzani</surname><given-names>P</given-names></name><name><surname>D'Argenio</surname><given-names>V</given-names></name><name><surname>Del Re</surname><given-names>M</given-names></name><name><surname>Pellegrini</surname><given-names>C</given-names></name><name><surname>Cucchiara</surname><given-names>F</given-names></name><name><surname>Salvianti</surname><given-names>F</given-names></name><name><surname>Galbiati</surname><given-names>S</given-names></name></person-group><article-title>Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors</article-title><source>Clin Chem Lab Med</source><volume>59</volume><fpage>1181</fpage><lpage>1200</lpage><year>2021</year><pub-id pub-id-type="pmid">33544478</pub-id><pub-id pub-id-type="doi">10.1515/cclm-2020-1685</pub-id></element-citation></ref>
<ref id="b9-WASJ-6-1-00221"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>LE</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer</article-title><source>Cancer Lett</source><volume>376</volume><fpage>83</fpage><lpage>94</lpage><year>2016</year><pub-id pub-id-type="pmid">26975632</pub-id><pub-id pub-id-type="doi">10.1016/j.canlet.2016.03.013</pub-id></element-citation></ref>
<ref id="b10-WASJ-6-1-00221"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gankyrin as potential biomarker for colorectal cancer with occult liver metastases</article-title><source>Front Oncol</source><volume>11</volume><issue>656852</issue><year>2021</year><pub-id pub-id-type="pmid">34395241</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2021.656852</pub-id></element-citation></ref>
<ref id="b11-WASJ-6-1-00221"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Lou</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name></person-group><article-title>The long non-coding RNA Linc-GALH promotes hepatocellular carcinoma metastasis via epigenetically regulating Gankyrin</article-title><source>Cell Death Dis</source><volume>10</volume><issue>86</issue><year>2019</year><pub-id pub-id-type="pmid">30692513</pub-id><pub-id pub-id-type="doi">10.1038/s41419-019-1348-0</pub-id></element-citation></ref>
<ref id="b12-WASJ-6-1-00221"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashitsuji</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Nagao</surname><given-names>T</given-names></name><name><surname>Dawson</surname><given-names>S</given-names></name><name><surname>Nonoguchi</surname><given-names>K</given-names></name><name><surname>Kido</surname><given-names>T</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name><name><surname>Arii</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>J</given-names></name></person-group><article-title>Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas</article-title><source>Nat Med</source><volume>6</volume><fpage>96</fpage><lpage>99</lpage><year>2000</year><pub-id pub-id-type="pmid">10613832</pub-id><pub-id pub-id-type="doi">10.1038/71600</pub-id></element-citation></ref>
<ref id="b13-WASJ-6-1-00221"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahangiri</surname><given-names>R</given-names></name><name><surname>Mosaffa</surname><given-names>F</given-names></name><name><surname>EmamiRazavi</surname><given-names>A</given-names></name><name><surname>Gharib</surname><given-names>M</given-names></name><name><surname>Jamialahmadi</surname><given-names>K</given-names></name></person-group><article-title>Increased expression of gankyrin and stemness factor oct-4 are associated with unfavorable clinical outcomes and poor benefit of tamoxifen in breast carcinoma patients</article-title><source>Pathol Oncol Res</source><volume>26</volume><fpage>1921</fpage><lpage>1934</lpage><year>2020</year><pub-id pub-id-type="pmid">31853860</pub-id><pub-id pub-id-type="doi">10.1007/s12253-019-00766-2</pub-id></element-citation></ref>
<ref id="b14-WASJ-6-1-00221"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho-Moll</surname><given-names>ME</given-names></name><name><surname>Macdonald</surname><given-names>J</given-names></name><name><surname>Looijenga</surname><given-names>LHJ</given-names></name><name><surname>Rimmer</surname><given-names>MP</given-names></name><name><surname>Donat</surname><given-names>R</given-names></name><name><surname>Marwick</surname><given-names>JA</given-names></name><name><surname>Shukla</surname><given-names>CJ</given-names></name><name><surname>Carragher</surname><given-names>N</given-names></name><name><surname>Jørgensen</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>RT</given-names></name></person-group><article-title>The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells</article-title><source>BMC Cancer</source><volume>19</volume><issue>1124</issue><year>2019</year><pub-id pub-id-type="pmid">31744479</pub-id><pub-id pub-id-type="doi">10.1186/s12885-019-6340-7</pub-id></element-citation></ref>
<ref id="b15-WASJ-6-1-00221"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhen</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name></person-group><article-title>Gankyrin as a potential target for tumor therapy: evidence and perspectives</article-title><source>Am J Transl Res</source><volume>10</volume><fpage>1949</fpage><lpage>1960</lpage><year>2018</year><pub-id pub-id-type="pmid">30093934</pub-id></element-citation></ref>
<ref id="b16-WASJ-6-1-00221"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>SQ</given-names></name><name><surname>Cao</surname><given-names>HF</given-names></name><name><surname>Wu</surname><given-names>MC</given-names></name></person-group><article-title>Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance</article-title><source>World J Gastroenterol</source><volume>8</volume><fpage>638</fpage><lpage>643</lpage><year>2002</year><pub-id pub-id-type="pmid">12174370</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v8.i4.638</pub-id></element-citation></ref>
<ref id="b17-WASJ-6-1-00221"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway</article-title><source>Cell Death Dis</source><volume>6</volume><issue>e1751</issue><year>2015</year><pub-id pub-id-type="pmid">25950481</pub-id><pub-id pub-id-type="doi">10.1038/cddis.2015.120</pub-id></element-citation></ref>
<ref id="b18-WASJ-6-1-00221"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Interleukin-1beta/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis</article-title><source>Hepatology</source><volume>61</volume><fpage>585</fpage><lpage>597</lpage><year>2015</year><pub-id pub-id-type="pmid">25294684</pub-id><pub-id pub-id-type="doi">10.1002/hep.27551</pub-id></element-citation></ref>
<ref id="b19-WASJ-6-1-00221"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Mo</surname><given-names>H</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name></person-group><article-title>Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significance</article-title><source>Sci Rep</source><volume>4</volume><issue>5503</issue><year>2014</year><pub-id pub-id-type="pmid">24999092</pub-id><pub-id pub-id-type="doi">10.1038/srep05503</pub-id></element-citation></ref>
<ref id="b20-WASJ-6-1-00221"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wurmbach</surname><given-names>E</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><name><surname>Fiel</surname><given-names>MI</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Thung</surname><given-names>SN</given-names></name><name><surname>Khitrov</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><etal/></person-group><article-title>A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis</article-title><source>Gastroenterol</source><volume>131</volume><fpage>1758</fpage><lpage>1767</lpage><year>2006</year><pub-id pub-id-type="pmid">17087938</pub-id><pub-id pub-id-type="doi">10.1053/j.gastro.2006.09.014</pub-id></element-citation></ref>
<ref id="b21-WASJ-6-1-00221"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Qian</surname><given-names>YW</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Ren</surname><given-names>YB</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Cao</surname><given-names>GW</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways</article-title><source>Hepatology</source><volume>53</volume><fpage>181</fpage><lpage>192</lpage><year>2011</year><pub-id pub-id-type="pmid">21254169</pub-id><pub-id pub-id-type="doi">10.1002/hep.24015</pub-id></element-citation></ref>
<ref id="b22-WASJ-6-1-00221"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>A</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Kiuchi</surname><given-names>T</given-names></name><name><surname>Higashitsuji</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>J</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name></person-group><article-title>Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation</article-title><source>J Gastroenterol</source><volume>38</volume><fpage>751</fpage><lpage>758</lpage><year>2003</year><pub-id pub-id-type="pmid">14505129</pub-id><pub-id pub-id-type="doi">10.1007/s00535-003-1141-8</pub-id></element-citation></ref>
<ref id="b23-WASJ-6-1-00221"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>Dedifferentiation of hepatocellular carcinoma: Molecular mechanisms and therapeutic implications</article-title><source>Am J Transl Res</source><volume>12</volume><fpage>2099</fpage><lpage>2109</lpage><year>2020</year><pub-id pub-id-type="pmid">32509204</pub-id></element-citation></ref>
<ref id="b24-WASJ-6-1-00221"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Nie</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Pei</surname><given-names>T</given-names></name><etal/></person-group><article-title>KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling</article-title><source>Oncogene</source><volume>38</volume><fpage>406</fpage><lpage>420</lpage><year>2019</year><pub-id pub-id-type="pmid">30115976</pub-id><pub-id pub-id-type="doi">10.1038/s41388-018-0440-8</pub-id></element-citation></ref>
<ref id="b25-WASJ-6-1-00221"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WP</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>JB</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Ni</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>JZ</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>ZP</given-names></name><etal/></person-group><article-title>Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling pathway</article-title><source>Oncotarget</source><volume>8</volume><fpage>5909</fpage><lpage>5923</lpage><year>2017</year><pub-id pub-id-type="pmid">27992365</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.13947</pub-id></element-citation></ref>
<ref id="b26-WASJ-6-1-00221"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="pmid">11846609</pub-id><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></element-citation></ref>
<ref id="b27-WASJ-6-1-00221"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oussalah</surname><given-names>A</given-names></name><name><surname>Rischer</surname><given-names>S</given-names></name><name><surname>Bensenane</surname><given-names>M</given-names></name><name><surname>Conroy</surname><given-names>G</given-names></name><name><surname>Filhine-Tresarrieu</surname><given-names>P</given-names></name><name><surname>Debard</surname><given-names>R</given-names></name><name><surname>Forest-Tramoy</surname><given-names>D</given-names></name><name><surname>Josse</surname><given-names>T</given-names></name><name><surname>Reinicke</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma mSEPT9: A novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma</article-title><source>EBioMedicine</source><volume>30</volume><fpage>138</fpage><lpage>147</lpage><year>2018</year><pub-id pub-id-type="pmid">29627389</pub-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.03.029</pub-id></element-citation></ref>
<ref id="b28-WASJ-6-1-00221"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Diplas</surname><given-names>BH</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy</article-title><source>Proc Natl Acad Sci USA</source><volume>116</volume><fpage>6308</fpage><lpage>6312</lpage><year>2019</year><pub-id pub-id-type="pmid">30858324</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1819799116</pub-id></element-citation></ref>
<ref id="b29-WASJ-6-1-00221"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>RH</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Krawczyk</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Flagg</surname><given-names>K</given-names></name><name><surname>Yi</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Quan</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma</article-title><source>Nat Mater</source><volume>16</volume><fpage>1155</fpage><lpage>1161</lpage><year>2017</year><pub-id pub-id-type="pmid">29035356</pub-id><pub-id pub-id-type="doi">10.1038/nmat4997</pub-id></element-citation></ref>
<ref id="b30-WASJ-6-1-00221"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisiel</surname><given-names>JB</given-names></name><name><surname>Dukek</surname><given-names>BA</given-names></name><name><surname>Kanipakam</surname><given-names>RVS</given-names></name><name><surname>Ghoz</surname><given-names>HM</given-names></name><name><surname>Yab</surname><given-names>TC</given-names></name><name><surname>Berger</surname><given-names>CK</given-names></name><name><surname>Taylor</surname><given-names>WR</given-names></name><name><surname>Foote</surname><given-names>PH</given-names></name><name><surname>Giama</surname><given-names>NH</given-names></name><name><surname>Onyirioha</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma detection by plasma methylated DNA: Discovery, phase I pilot, and phase II clinical validation</article-title><source>Hepatology</source><volume>69</volume><fpage>1180</fpage><lpage>1192</lpage><year>2019</year><pub-id pub-id-type="pmid">30168613</pub-id><pub-id pub-id-type="doi">10.1002/hep.30244</pub-id></element-citation></ref>
<ref id="b31-WASJ-6-1-00221"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Yang</surname><given-names>SR</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Cho</surname><given-names>HC</given-names></name><name><surname>Shim</surname><given-names>SG</given-names></name><name><surname>Paik</surname><given-names>YH</given-names></name></person-group><article-title>Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma</article-title><source>Exp Mol Med</source><volume>47</volume><issue>e184</issue><year>2015</year><pub-id pub-id-type="pmid">26380927</pub-id><pub-id pub-id-type="doi">10.1038/emm.2015.68</pub-id></element-citation></ref>
<ref id="b32-WASJ-6-1-00221"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Felden</surname><given-names>J</given-names></name><name><surname>Schulze</surname><given-names>K</given-names></name><name><surname>Krech</surname><given-names>T</given-names></name><name><surname>wald</surname><given-names>F</given-names></name><name><surname>Nashan</surname><given-names>B</given-names></name><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>Riethdorf</surname><given-names>S</given-names></name><name><surname>Wege</surname><given-names>H</given-names></name></person-group><article-title>Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection</article-title><source>Oncotarget</source><volume>8</volume><fpage>89978</fpage><lpage>89987</lpage><year>2017</year><pub-id pub-id-type="pmid">29163804</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.21208</pub-id></element-citation></ref>
<ref id="b33-WASJ-6-1-00221"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YF</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>XR</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>SJ</given-names></name><name><surname>Shi</surname><given-names>RY</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection</article-title><source>Hepatology</source><volume>57</volume><fpage>1458</fpage><lpage>1468</lpage><year>2013</year><pub-id pub-id-type="pmid">23175471</pub-id><pub-id pub-id-type="doi">10.1002/hep.26151</pub-id></element-citation></ref>
<ref id="b34-WASJ-6-1-00221"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogle</surname><given-names>LF</given-names></name><name><surname>Orr</surname><given-names>JG</given-names></name><name><surname>Willoughby</surname><given-names>CE</given-names></name><name><surname>Hutton</surname><given-names>C</given-names></name><name><surname>McPherson</surname><given-names>S</given-names></name><name><surname>Plummer</surname><given-names>R</given-names></name><name><surname>Boddy</surname><given-names>AV</given-names></name><name><surname>Curtin</surname><given-names>NJ</given-names></name><name><surname>Jamieson</surname><given-names>D</given-names></name><name><surname>Reeves</surname><given-names>HL</given-names></name></person-group><article-title>Imagestream detection and characterisation of circulating tumour cells-A liquid biopsy for hepatocellular carcinoma?</article-title><source>J Hepatol</source><volume>65</volume><fpage>305</fpage><lpage>313</lpage><year>2016</year><pub-id pub-id-type="pmid">27132171</pub-id><pub-id pub-id-type="doi">10.1016/j.jhep.2016.04.014</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-WASJ-6-1-00221" position="float">
<label>Figure 1</label>
<caption><p>∆Ct of gankyrin mRNA in the blood plasma of patients with HCC and metastatic HCC. <sup>***</sup>P&lt;0.001; HCC, hepatocellular carcinoma.</p></caption>
<graphic xlink:href="wasj-06-01-00221-g00.tif"/>
</fig>
<fig id="f2-WASJ-6-1-00221" position="float">
<label>Figure 2</label>
<caption><p>Relative expression level (2<sup>-ΔΔCq</sup>) of gankyrin mRNA in tissue samples. <sup>*</sup>P&lt;0.05, <sup>**</sup>P&lt;0.01 and <sup>***</sup>P&lt;0.001. HCC, hepatocellular carcinoma; HCC ADJ T, hepatocellular carcinoma tumor adjacent tissue.</p></caption>
<graphic xlink:href="wasj-06-01-00221-g01.tif"/>
</fig>
<table-wrap id="tI-WASJ-6-1-00221" position="float">
<label>Table I</label>
<caption><p>Clinicopathological characteristics of the patients from whom plasma was collected.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Characteristic</th>
<th align="center" valign="middle">Patients with HCC (n=32)</th>
<th align="center" valign="middle">Patients with metastatic HCC disease (n=5)</th>
<th align="center" valign="middle">Patients with cirrhosis (n=7)</th>
<th align="center" valign="middle">HCV-positive patients (n=5)</th>
<th align="center" valign="middle">Healthy individuals (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Sex, n (%)</td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">     Male</td>
<td align="center" valign="middle">27 (84.4)</td>
<td align="center" valign="middle">5(100)</td>
<td align="center" valign="middle">6 (85.7)</td>
<td align="center" valign="middle">4(80)</td>
<td align="center" valign="middle">4(80)</td>
</tr>
<tr>
<td align="left" valign="middle">     Female</td>
<td align="center" valign="middle">5 (15.6)</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1 (14.3)</td>
<td align="center" valign="middle">1(20)</td>
<td align="center" valign="middle">1(20)</td>
</tr>
<tr>
<td align="left" valign="middle">Age, years</td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">     Mean (SD)</td>
<td align="center" valign="middle">55.7 (5.7)</td>
<td align="center" valign="middle">57.4 (3.6)</td>
<td align="center" valign="middle">57.1 (2.9)</td>
<td align="center" valign="middle">49.4 (1.7)</td>
<td align="center" valign="middle">50.0 (4.1)</td>
</tr>
<tr>
<td align="left" valign="middle">     Median</td>
<td align="center" valign="middle">57.5</td>
<td align="center" valign="middle">58</td>
<td align="center" valign="middle">56</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">50</td>
</tr>
<tr>
<td align="left" valign="middle">     Range</td>
<td align="center" valign="middle">46-66</td>
<td align="center" valign="middle">52-62</td>
<td align="center" valign="middle">53-61</td>
<td align="center" valign="middle">48-52</td>
<td align="center" valign="middle">45-55</td>
</tr>
<tr>
<td align="left" valign="middle">Child-Pugh class, n (%)</td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">     A</td>
<td align="center" valign="middle">18 (56.3)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="left" valign="middle">     B</td>
<td align="center" valign="middle">10 (31.3)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="left" valign="middle">     C</td>
<td align="center" valign="middle">4 (12.5)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>HCC, hepatocellular carcinoma; SD, standard deviation; NA, not applicable.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-WASJ-6-1-00221" position="float">
<label>Table II</label>
<caption><p>Clinicopathological characteristics of the patients undergoing liver tissue biopsy.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Characteristic</th>
<th align="center" valign="middle">Patients with cirrhosis (n=5)</th>
<th align="center" valign="middle">Healthy individuals (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Sex, n (%)</td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle">n (%)</td>
</tr>
<tr>
<td align="left" valign="middle">     Male</td>
<td align="center" valign="middle">5(100)</td>
<td align="center" valign="middle">4(80)</td>
</tr>
<tr>
<td align="left" valign="middle">     Female</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1(20)</td>
</tr>
<tr>
<td align="left" valign="middle">Age, years</td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">     Mean (SD)</td>
<td align="center" valign="middle">50.4 (2.1)</td>
<td align="center" valign="middle">35.6 (3.04)</td>
</tr>
<tr>
<td align="left" valign="middle">     Median</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">35</td>
</tr>
<tr>
<td align="left" valign="middle">     Range</td>
<td align="center" valign="middle">48-53</td>
<td align="center" valign="middle">32-40</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>SD, standard deviation.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
